Myasthenic Syndromes, Congenital – Talk Bio

Actionable Insights Powered by AI

AstraZeneca Appeals to Supreme Court in Final Attempt to Challenge Medicare Drug Price Negotiation Program

1 month ago talkbio0Tagged AstraZeneca, drug price, Farxiga, Inflation Reduction Act, Medicare, Myasthenic Syndromes, Congenital, Negotiation Program, Supreme Court

AstraZeneca; Medicare Drug Price Negotiation Program; Supreme Court; Inflation Reduction Act; Third Circuit; due process; pharmaceuticals; CMS; drug pricing; Farxiga

Two Courts Reject Challenges to Inflation Reduction Act, Marking Major Win for Government

3 months ago talkbio0Tagged administrative law, AstraZeneca, constitutional challenge, Drug Negotiation Program, federal courts, Inflation, Ira (eukaryote), Medicare, Myasthenic Syndromes, Congenital, Third Circuit Court

Inflation Reduction Act; IRA; Medicare Drug Negotiation Program; AstraZeneca; federal courts; constitutional challenge; administrative law; Third Circuit Court; CMS; Medicare

Trump Taps Dr. Oz as Lead Negotiator for ‘Most Favored Nation’ Drug Pricing Policy

5 months ago talkbio0Tagged Dr., Drug Costs, drug price, Health Policy, Myasthenic Syndromes, Congenital, Nation, ounce, pharmaceutical negotiations, Transplant Registry Unified Management Program

Trump; Dr. Mehmet Oz; Most Favored Nation; drug pricing; CMS; pharmaceutical negotiations; healthcare policy; drug costs

IRA round 2 begins as drugmakers sign on to price negotiation process with CMS

7 months ago talkbio0Tagged drugmakers, Ira (eukaryote), Mediation, Medicare, Myasthenic Syndromes, Congenital, Prices

Myasthenic Syndromes, Congenital, Mediation, Prices, Medicare, Ira (eukaryote), drugmakers

Trump’s Healthcare Nominees Pledge to Divest Industry Investments Amid Controversy

8 months ago talkbio0Tagged Bhattacharya, healthcare appointments, Industry, Jay, Jr., Mehmet, Myasthenic Syndromes, Congenital, NIH, NIH Mouse, ounce, ties, Transplant Registry Unified Management Program

Trump administration, healthcare appointments, NIH, CMS, divestment, industry ties, Jay Bhattacharya, Mehmet Oz, Robert F. Kennedy Jr.

Massive Layoffs Sweep Federal Health Agencies: Thousands of Workers Impacted Across HHS

8 months ago talkbio0Tagged Administration occupational activities, Centers for Disease Control and Prevention (U.S.), federal, Health agencies, HHS layoffs, Myasthenic Syndromes, Congenital, NIH, NIH Mouse, probationary workers, Transplant Registry Unified Management Program, United States Food and Drug Administration

HHS layoffs, federal health agencies, probationary workers, Trump administration, workforce reduction, CDC, NIH, FDA, CMS

DOGE Access to Treasury Systems Restricted Amid Concerns Over CMS Scrutiny

9 months ago talkbio0Tagged concerns, DOGE, Elon, federal, Musk secretion from Musk Deer, Myasthenic Syndromes, Congenital, Patient location type - Department, payment, Privacy

Elon Musk, DOGE, Treasury Department, CMS, payment systems, privacy concerns, lawsuit, federal court order

Understanding the Second Round of Medicare Drug Price Negotiations: What Trump’s CMS Can and Can’t Change

9 months ago talkbio0Tagged Administration occupational activities, CMS, drug price, Inflation, Medicare, Myasthenic Syndromes, Congenital, negotiation, Prices, Transplant Registry Unified Management Program

Medicare drug price negotiation, Trump administration, CMS, Inflation Reduction Act, drug prices, negotiation process

CMS Approves Transitional Pass-Through Payments for Renal Denervation Systems from Medtronic and Recor Medical

12 months ago talkbio0Tagged Hypertensive disease, Medtronic, Myasthenic Syndromes, Congenital, Payments, Recor Medical, Renal Denervation Systems, Transitional cell morphology

Renal Denervation Systems, CMS, Transitional Pass-Through Payments, Medtronic, Recor Medical, Hypertension Treatment

CMS Unveils Preliminary List of 101 Generic Drugs for Medicare $2 Out-of-Pocket Plan

1 year ago talkbio0Tagged Adherence (attribute), Drug List, Expenditures, Out-of-Pocket, Health Outcomes, innovation, Medicare, Myasthenic Syndromes, Congenital

Medicare $2 Drug List Model, generic drugs, out-of-pocket costs, medication adherence, health outcomes, CMS Innovation Center